222 related articles for article (PubMed ID: 10466241)
21. [Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Aumiller J
MMW Fortschr Med; 2006 Mar; 148(12):4-6, 8. PubMed ID: 16625995
[No Abstract] [Full Text] [Related]
22. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
23. [Chemotherapy in metastasized breast carcinoma].
Bontenbal M; de Wit R; Klijn JG; Seynaeve C
Ned Tijdschr Geneeskd; 1998 Jul; 142(30):1709-13. PubMed ID: 9763866
[TBL] [Abstract][Full Text] [Related]
24. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
25. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
26. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
27. New developments in the treatment of postmenopausal breast cancer.
Howell A
Trends Endocrinol Metab; 2005 Nov; 16(9):420-8. PubMed ID: 16213745
[TBL] [Abstract][Full Text] [Related]
28. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
29. Metastatic breast cancer.
Kennedy MJ
Curr Opin Oncol; 1996 Nov; 8(6):485-90. PubMed ID: 8971468
[TBL] [Abstract][Full Text] [Related]
30. Letrozole: advancing hormone therapy in breast cancer.
Lee RJ; Armstrong AC; Wardley AM
Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
[TBL] [Abstract][Full Text] [Related]
31. Overcoming recurrence risk: extended adjuvant endocrine therapy.
Cianfrocca M
Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
[TBL] [Abstract][Full Text] [Related]
32. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
33. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
34. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
36. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
37. Taxanes in the treatment of breast cancer: a prodigy comes of age.
Miller KD; Sledge GW
Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
[TBL] [Abstract][Full Text] [Related]
38. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
39. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
40. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
